About Convert Pharmaceuticals
Convert Pharmaceuticals is a company based in Liege (Belgium) founded in 2017 by Philippe Lambin. It operates as a HealthTech. Convert Pharmaceuticals has raised $16.72 million across 3 funding rounds from investors including European Union, EIC Fund and Noshaq. The company has 2 employees as of December 31, 2022. Convert Pharmaceuticals offers products and services including Tumor Microenvironment Prodrugs. Convert Pharmaceuticals operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
- Headquarter Liege, Belgium
- Employees 2 as on 31 Dec, 2022
- Founders Philippe Lambin
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Convert Pharmaceuticals Sa
-
Annual Revenue
-
Net Profit
$-328 K (USD)21as on Dec 31, 2021
-
EBITDA
$-332.14 K (USD)20as on Dec 31, 2021
-
Total Equity Funding
$16.72 M (USD)
in 3 rounds
-
Latest Funding Round
$2.72 M (USD), Grant
Jan 01, 2024
-
Investors
European Union
& 3 more
-
Employee Count
2
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Convert Pharmaceuticals
Convert Pharmaceuticals offers a comprehensive portfolio of products and services, including Tumor Microenvironment Prodrugs. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Prodrugs are developed to target tumor hypoxia effectively.
Unlock access to complete
Unlock access to complete
Funding Insights of Convert Pharmaceuticals
Convert Pharmaceuticals has successfully raised a total of $16.72M across 3 strategic funding rounds. The most recent funding activity was a Grant round of $2.72 million completed in January 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Grant — $2.7M
-
First Round
First Round
(28 Feb 2018)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2024 | Amount | Grant - Convert Pharmaceuticals | Valuation |
investors |
|
| Jun, 2023 | Amount | Grant - Convert Pharmaceuticals | Valuation |
investors |
|
| Feb, 2018 | Amount | Series A - Convert Pharmaceuticals | Valuation | Noshaq , Droia |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Convert Pharmaceuticals
Convert Pharmaceuticals has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include European Union, EIC Fund and Noshaq. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Founded Year | Domain | Location | |
|
Noshaq is recognized as a Liège-based investment fund providing financing solutions.
|
Founded Year | Domain | Location | |
|
Droia Ventures is focused on investing in drug development companies.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Convert Pharmaceuticals
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Convert Pharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Convert Pharmaceuticals Comparisons
Competitors of Convert Pharmaceuticals
Convert Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| domain | founded_year | HQ Location |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| domain | founded_year | HQ Location |
Therapeutics for cancer and rare diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Convert Pharmaceuticals
Frequently Asked Questions about Convert Pharmaceuticals
When was Convert Pharmaceuticals founded?
Convert Pharmaceuticals was founded in 2017 and raised its 1st funding round 1 year after it was founded.
Where is Convert Pharmaceuticals located?
Convert Pharmaceuticals is headquartered in Liege, Belgium. It is registered at Liege, Liege, Belgium.
Is Convert Pharmaceuticals a funded company?
Convert Pharmaceuticals is a funded company, having raised a total of $16.72M across 3 funding rounds to date. The company's 1st funding round was a Series A of $16.72M, raised on Feb 28, 2018.
How many employees does Convert Pharmaceuticals have?
As of Dec 31, 2022, the latest employee count at Convert Pharmaceuticals is 2.
What does Convert Pharmaceuticals do?
Convert Pharmaceuticals is engaged in the development of innovative prodrugs designed to activate within the tumor microenvironment. These prodrugs are crafted to target tumor hypoxia, a key factor in cancer treatment resistance, affecting around 50 of solid tumors. The companys solutions address specific cancer types, including pancreatic, ovarian, breast, prostate, and head and neck squamous cell carcinoma. Proprietary insights into tumor biology and biomarkers are utilized to enhance the efficacy of these therapies. The biotechnology sector is primarily served through cutting-edge research and strategic partnerships.
Who are the top competitors of Convert Pharmaceuticals?
Convert Pharmaceuticals's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
What products or services does Convert Pharmaceuticals offer?
Convert Pharmaceuticals offers Tumor Microenvironment Prodrugs.
Who are Convert Pharmaceuticals's investors?
Convert Pharmaceuticals has 4 investors. Key investors include European Union, EIC Fund, Noshaq, and Droia Ventures.